

February 13, 2025

Company name:	Mitsubishi Chemical Group Corporation
Representative:	Manabu Chikumoto Representative Corporate Executive Officer, President & Chief Executive Officer Listed on The Prime Market TSE (stock code:4188)
Tel:	[Media] [+81] (0)3-6748-7140 [IR] [+81] (0)3-6748-7120

**“Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (Under IFRS)”
Partial Corrections in Disclosure Matters And Completion of Interim Review for by an Independent Auditor**

Mitsubishi Chemical Group Corporation (MCG) hereby announces that there have been corrections made to “Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (Under IFRS)” released on February 6, 2025. Note that no corrections have been made to numerical data. And the interim review of the Japanese Originals of the MCG's Condensed Consolidated Financial Statements in the above-mentioned disclosure material, has been completed by an independent auditor.

Note that The English translation of the quarterly consolidated financial results did not receive a quarterly review by certified public accountants or an audit firm.

1.Details of the revision

【page 20】

Added descriptions to the following section.

2. Condensed Consolidated Financial Statements

and Notes Concerning Condensed Consolidated Financial Statements

(6) Notes to Condensed Consolidated Financial Statements (Material Subsequent Events)

【Before revision】

Not applicable

【After revision】

(The Transfer of Mitsubishi Tanabe Pharma Corporation and its Subsidiaries)

The Group has resolved, at a meeting of the Board of Directors held today, to transfer its consolidated subsidiary, Mitsubishi Tanabe Pharma Corporation (“MTPC”), which engages in the manufacturing and sales of pharmaceutical products, to K.K. BCJ-94, a special purpose company indirectly owned by funds advised by Bain Capital Private Equity, LP (together with its affiliates, “Bain Capital”)(the “Transfer”), and an agreement related to the Transfer was signed on the same day.

The specific method of this Transfer is currently under review and the completion of the Transfer is expected in the second quarter of FY 3/2026, subject to certain conditions including approval of the Transfer at MCG's annual shareholders' meeting and Bain Capital's obtainment of necessary clearance and approval pursuant to the competition laws and related laws and regulations of Japan and other relevant jurisdictions.

Following approval of the Transfer at MCG's annual shareholders' meeting, MTPC, its subsidiaries and affiliate will be categorized as discontinued operations. MCG expects to record pre-tax income from discontinued operations of approximately 95 billion yen in the second quarter of FY2025 in relation to the

Transfer. However, this number may differ from the final result although it is predicted based on the financial results as of end of December 2024.

2.Reasons for the above revision

Notes have been added because a significant subsequent event occurred in MCG after the announcement of the quarterly financial results for the third quarter on February 6, 2025.